Last reviewed · How we verify

Chinese herbal formula (CCH1)

National Taiwan University Hospital · Phase 3 active Small molecule

Chinese herbal formula (CCH1) is a Small molecule drug developed by National Taiwan University Hospital. It is currently in Phase 3 development. Also known as: TCM.

A Chinese herbal formula that modulates multiple biological pathways to produce therapeutic effects, though the precise mechanism remains incompletely characterized.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030 —
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameChinese herbal formula (CCH1)
Also known asTCM
SponsorNational Taiwan University Hospital
ModalitySmall molecule
PhasePhase 3

Mechanism of action

Chinese herbal formulas typically contain multiple plant-derived compounds that act synergistically on various molecular targets and physiological systems. CCH1 is in phase 3 development at National Taiwan University Hospital, but without published mechanism data, the specific molecular targets and pathways involved are not publicly detailed. The therapeutic effects likely result from combined anti-inflammatory, antioxidant, or immunomodulatory activities of constituent herbs.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Chinese herbal formula (CCH1)

What is Chinese herbal formula (CCH1)?

Chinese herbal formula (CCH1) is a Small molecule drug developed by National Taiwan University Hospital.

How does Chinese herbal formula (CCH1) work?

A Chinese herbal formula that modulates multiple biological pathways to produce therapeutic effects, though the precise mechanism remains incompletely characterized.

Who makes Chinese herbal formula (CCH1)?

Chinese herbal formula (CCH1) is developed by National Taiwan University Hospital (see full National Taiwan University Hospital pipeline at /company/national-taiwan-university-hospital).

Is Chinese herbal formula (CCH1) also known as anything else?

Chinese herbal formula (CCH1) is also known as TCM.

What development phase is Chinese herbal formula (CCH1) in?

Chinese herbal formula (CCH1) is in Phase 3.

Related